Impact of Virgin Coconut Oil and Carvedilol on Neurobehaviour, Apoptotic and Inflammatory Brain Markers in Doxorubicin Treated Mice
Abstract
Keywords
Full Text:
PDFReferences
1. Ahles, T. A., & Saykin, A. (2001). Cognitive Effects of Standard-Dose Chemotherapy in Patients with Cancer. Cancer Investigation, 19(8), 812–820. doi: 10.1081/cnv-100107743
2. Olin J. J. (2001). Cognitive function after systemic therapy for breast cancer. Oncology, 15(5), 613–624.
3. Hayslip, J., Dressler, E. V., Weiss, H., Taylor, T. J., Chambers, M., Noel, T., Miriyala, S., Keeney, J. T. R., Ren, X., Sultana, R., Vore, M., Butterfield, D. A., St Clair, D., & Moscow, J. A. (2015). Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna—A Randomized, Cross-Over Clinical Study. PLOS ONE, 10(4), e0124988. doi: 10.1371/journal.pone.0124988
4. Correa, D. D., & Ahles, T. A. (2008). Neurocognitive Changes in Cancer Survivors. The Cancer Journal, 14(6), 396–400. doi: 10.1097/ppo.0b013e31818d8769
5. Aluise, C. D., Sultana, R., Tangpong, J., Vore, M., Clair, D. St., Moscow, J. A., & Butterfield, D. A. (2010). Chemo Brain (Chemo Fog) as a Potential Side Effect of Doxorubicin Administration: Role of Cytokine-Induced, Oxidative/Nitrosative Stress in Cognitive Dysfunction. Advances in Experimental Medicine and Biology, 147–156. doi: 10.1007/978-1-4419-6306-2_19
6. Weiss R. B. (1992). The anthracyclines: will we ever find a better doxorubicin? Seminars in oncology, 19(6), 670–686.
7. Volkova, M., & Russell, R. (2012). Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Current Cardiology Reviews, 7(4), 214–220. doi: 10.2174/157340311799960645
8. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews, 56(2), 185–229. doi: 10.1124/pr.56.2.6
9. Zordoky, B. N. M., Anwar-Mohamed, A., Aboutabl, M. E., & El-Kadi, A. O. S. (2011). Acute Doxorubicin Toxicity Differentially Alters Cytochrome P450 Expression and Arachidonic Acid Metabolism in Rat Kidney and Liver. Drug Metabolism and Disposition, 39(8), 1440–1450. doi: 10.1124/dmd.111.039123
10. Jansen, C. E., Dodd, M. J., Miaskowski, C. A., Dowling, G. A., & Kramer, J. (2008). Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psycho-Oncology, 17(12), 1189–1195. doi: 10.1002/pon.1342
11. Wefel, J. S., Lenzi, R., Theriault, R. L., Davis, R. N., & Meyers, C. A. (2004). The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinoma. Cancer, 100(11), 2292–2299. doi: 10.1002/cncr.20272
12. Wefel, J. S., Saleeba, A. K., Buzdar, A. U., & Meyers, C. A. (2010). Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer, 116(14), 3348–3356. doi: 10.1002/cncr.25098
13. Tangpong, J., Cole, M. P., Sultana, R., Estus, S., Vore, M., St. Clair, W., Ratanachaiyavong, S., St. Clair, D. K., & Butterfield, D. A. (2006). Adriamycin‐mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. Journal of Neurochemistry, 100(1), 191–201. doi: 10.1111/j.1471-4159.2006.04179.x
14. Tangpong, J., Cole, M. P., Sultana, R., Joshi, G., Estus, S., Vore, M., St. Clair, W., Ratanachaiyavong, S., St. Clair, D. K., & Butterfield, D. A. (2006). Adriamycin-induced, TNF-α-mediated central nervous system toxicity. Neurobiology of Disease, 23(1), 127–139. doi: 10.1016/j.nbd.2006.02.013
15. Cardoso, S., Santos, R. X., Carvalho, C., Correia, S., Pereira, G. C., Pereira, S. S., Oliveira, P. J., Santos, M. S., Proença, T., & Moreira, P. I. (2008). Doxorubicin increases the susceptibility of brain mitochondria to Ca2+-induced permeability transition and oxidative damage. Free Radical Biology and Medicine, 45(10), 1395–1402. doi: 10.1016/j.freeradbiomed.2008.08.008
16. Gao, Y., Xu, Y., Hua, S., Zhou, S., & Wang, K. (2015). ALDH2 attenuates Dox-induced cardiotoxicity by inhibiting cardiac apoptosis and oxidative stress. International journal of clinical and experimental medicine, 8(5), 6794–6803.
17. Zhang, R., Kang, X., Wang, Y., Wang, F., Yu, P., Shen, J., & Fu, L. (2016). Effects of carvedilol on ventricular remodeling and the expression of β 3 -adrenergic receptor in a diabetic rat model subjected myocardial infarction. International Journal of Cardiology, 222, 178–184. doi: 10.1016/j.ijcard.2016.07.188
19. Tacar, O., Indumathy, S., Tan, M. L., Baindur-Hudson, S., Friedhuber, A. M., & Dass, C. R. (2014). Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cells. Journal of Pharmacy and Pharmacology, 67(2), 231–243. doi: 10.1111/jphp.12324
20. Deus, C. M., Zehowski, C., Nordgren, K., Wallace, K. B., Skildum, A., & Oliveira, P. J. (2015). Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling in H9c2 cardiomyoblasts. Toxicology, 334, 1–11. doi: 10.1016/j.tox.2015.05.001
21. Mitry, M. A., & Edwards, J. G. (2016). Doxorubicin induced heart failure: Phenotype and molecular mechanisms. IJC Heart & Vasculature, 10, 17–24. doi: 10.1016/j.ijcha.2015.11.004
22. Jhorawat, R., Kumari, S., Varma, S., Rohit, M., Narula, N., Suri, V., Malhotra, P., & Jain, S. (2016). Preventive role of carvedilol in adriamycin-induced cardiomyopathy. Indian Journal of Medical Research, 144(5), 725. doi: 10.4103/ijmr.ijmr_1323_14
23. Ibrahim, S. S., Barakat, M. A., & Helmy, H. S. (2010). Modulating Effect of Carvedilol on Doxorubicin-induced Cardiomyopathy and Hepatic Damage. Journal of American Science, 6(12), 20–32.
24. Fazio, S., Palmieri, E. A., Ferravante, B., Bon È, F., & Biondi, B. (1998). Doxorubicin‐induced cardiomyopathy treated with carvedilol. Clinical Cardiology, 21(10), 777–779. doi: 10.1002/clc.4960211017
25. Matsui, H., Morishima, I., Numaguchi, Y., Toki, Y., Okumura, K., & Hayakawa, T. (1999). Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sciences, 65(12), 1265–1274. doi: 10.1016/s0024-3205(99)00362-8
26. Chen, Y.-L., Chung, S.-Y., Chai, H.-T., Chen, C.-H., Liu, C.-F., Chen, Y.-L., Huang, T.-H., Zhen, Y.-Y., Sung, P.-H., Sun, C.-K., Chua, S., Lu, H.-I., Lee, F.-Y., Sheu, J.-J., & Yip, H.-K. (2015). Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. Journal of Pharmacology and Experimental Therapeutics, 355(3), 516–527. doi: 10.1124/jpet.115.225375
27. Tashakori Beheshti, A., Mostafavi Toroghi, H., Hosseini, G., Zarifian, A., Homaei Shandiz, F., & Fazlinezhad, A. (2016). Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial. Cardiology, 134(1), 47–53. doi: 10.1159/000442722
28. Singh, N., Tailang, M., & Mehta, S. (2016). A review on herbal plants as immunomodulators. IJPSR, 7(9), 3602–3610.
29. Song, Y. H., Sun, H., Zhang, A. H., Yan, G., Han, Y., & Wang, X. (2014). Plant derived natural products as leads to anti-cancer drugs. Journal of Medicinal Plant and Herbal Therapy Research, 2, 6–15.
30. Fife, B. (2003). The healing Miracles of Coconut Oil (3rd ed.). Colorado Springs: Piccadilly Books.
31. Halliwell, B., Rafter, J., & Jenner, A. (2005). Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? The American Journal of Clinical Nutrition, 81(1), 268S-276S. doi: 10.1093/ajcn/81.1.268s
32. Fife, B. (2006). Virgin coconut oil: Nature’s Miracle Medicine. Colorado Springs: Piccadilly Books.
33. Evangelista, M. T. P., Abad-Casintahan, F., & Lopez-Villafuerte, L. (2013). The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss, and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized, double-blind, clinical trial. International Journal of Dermatology, 53(1), 100–108. doi: 10.1111/ijd.12339
34. Magge, R. S., & DeAngelis, L. M. (2015). The double-edged sword: Neurotoxicity of chemotherapy. Blood Reviews, 29(2), 93–100. doi: 10.1016/j.blre.2014.09.012
33. Soffietti, R., Trevisan, E., & Rudà, R. (2014). Neurologic complications of chemotherapy and other newer and experimental approaches. Neurologic Aspects of Systemic Disease Part III, 1199–1218. doi: 10.1016/b978-0-7020-4088-7.00080-8
36. Plotkin, S. R., & Wen, P. Y. (2003). Neurologic complications of cancer therapy. Neurologic Clinics, 21(1), 279–318. doi: 10.1016/s0733-8619(02)00034-8
37. Javaid, H. I. (2020). Anatomy and Physiology of Brain in Context of Learning: A Review from Current Literature. Biomedical Journal of Scientific & Technical Research, 26(5). doi: 10.26717/bjstr.2020.26.004415
38. Basim, A., Fysal, N. Akhila, Thasneem, A., Aswathy, P. (2019). Assessment of knowledge level on learning disability among primary school teachers. International Journal of Contemporary Pediatrics, 6(2), 431–435.
39. Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (2000). Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Reprinted from Biotechnology and Bioengineering, Vol. XI, Issue 6, Pages 1101-1110 (1969). Biotechnology and bioengineering, 67(6), 704–713. doi: 10.1002/(sici)1097-0290(20000320)67:6<704::aid-bit8>3.0.co;2-l
40. Menna, P., Gonzalez Paz, O., Chello, M., Covino, E., Salvatorelli, E., & Minotti, G. (2011). Anthracycline cardiotoxicity. Expert Opinion on Drug Safety, 11(sup1), S21–S36. doi: 10.1517/14740338.2011.589834
41. Gewirtz, D. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 57(7), 727–741. doi: 10.1016/s0006-2952(98)00307-4
42. Sinha, B. K., Trush, M. A., Kennedy, K. A., & Mimnaugh, E. G. (1984). Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer research, 44(7), 2892–2896.
43. Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 52(6), 1213–1225. doi: 10.1016/j.yjmcc.2012.03.006
44. Kufe, D. W., Holland, J. F., Frei, E. (2003). Holland Frei cancer medicine. Hamilton: BC Decker
45. Kalyanaraman, B. (2020). Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biology, 29, 101394. doi: 10.1016/j.redox.2019.101394
46. Box, V. G. S. (2007). The intercalation of DNA double helices with doxorubicin and nagalomycin. Journal of Molecular Graphics and Modelling, 26(1), 14–19. doi: 10.1016/j.jmgm.2006.09.005
47. Keime-Guibert, F., Napolitano, M., & Delattre, J.-Y. (1998). Neurological complications of radiotherapy and chemotherapy. Journal of Neurology, 245(11), 695–708. doi: 10.1007/s004150050271
48. Lipp, H.-P. (1999). Anticancer drug toxicity prevention, management and clinical pharmacokinetics. New York: CRC Press.
49. Brezden, C. B., Phillips, K.-A., Abdolell, M., Bunston, T., & Tannock, I. F. (2000). Cognitive Function in Breast Cancer Patients Receiving Adjuvant Chemotherapy. Journal of Clinical Oncology, 18(14), 2695–2701. doi: 10.1200/jco.2000.18.14.2695
50. Schagen, S. B., van Dam, F. S., Muller, M. J., Boogerd, W., Lindeboom, J., & Bruning, P. F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85(3), 640–650. doi: 10.1002/(sici)1097-0142(19990201)85:3<640::aid-cncr14>3.0.co;2-g
51. van Dam, F. S. A. M., Boogerd, W., Schagen, S. B., Muller, M. J., Droogleever Fortuyn, M. E., Wall, E. v.d., & Rodenhuis, S. (1998). Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy. JNCI: Journal of the National Cancer Institute, 90(3), 210–218. doi: 10.1093/jnci/90.3.210
52. Wieneke, M. H., & Dienst, E. R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4(1), 61–66. doi: 10.1002/pon.2960040108
53. Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., Whedon, M. B., Bivens, S., Mitchell, T., Greenberg, E. R., & Silberfarb, P. M. (2002). Neuropsychologic Impact of Standard-Dose Systemic Chemotherapy in Long-Term Survivors of Breast Cancer and Lymphoma. Journal of Clinical Oncology, 20(2), 485–493. doi: 10.1200/jco.2002.20.2.485
54. Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q.-L., Hu, H., Chemerynsky, I., Clemons, M., Crump, M., Goss, P. E., Warr, D., Tweedale, M. E., & Tannock, I. F. (2003). Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 21(22), 4175–4183. doi: 10.1200/jco.2003.01.119
55. Jansen, C., Miaskowski, C., Dodd, M., Dowling, G., & Kramer, J. (2005). Potential Mechanisms for Chemotherapy-Induced Impairments in Cognitive Function. Oncology Nursing Forum, 32(6), 1151–1163. doi: 10.1188/05.onf.1151-1163
56. Bender, C. M., Sereika, S. M., Berga, S. L., Vogel, V. G., Brufsky, A. M., Paraska, K. K., & Ryan, C. M. (2005). Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology, 15(5), 422–430. doi: 10.1002/pon.964
57. Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., Bishop, H., Hodson, N., Mitra, S., Sadler, G., Shah, E., Stein, R., Whitehead, S., & Winstanley, J. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94(6), 828–834. doi: 10.1038/sj.bjc.6603029
58. Hurria, A., Rosen, C., Hudis, C., Zuckerman, E., Panageas, K. S., Lachs, M. S., Witmer, M., Van Gorp, W. G., Fornier, M., D’Andrea, G., Moasser, M., Dang, C., Van Poznak, C., Hurria, A., & Holland, J. (2006). Cognitive Function of Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer: A Pilot Prospective Longitudinal Study. Journal of the American Geriatrics Society, 54(6), 925–931. doi: 10.1111/j.1532-5415.2006.00732.x
59. Ferguson, R. J., McDonald, B. C., Saykin, A. J., & Ahles, T. A. (2007). Brain Structure and Function Differences in Monozygotic Twins: Possible Effects of Breast Cancer Chemotherapy. Journal of Clinical Oncology, 25(25), 3866–3870. doi: 10.1200/jco.2007.10.8639
60. Hermelink, K., Untch, M., Lux, M. P., Kreienberg, R., Beck, T., Bauerfeind, I., & Münzel, K. (2007). Cognitive function during neoadjuvant chemotherapy for breast cancer. Cancer, 109(9), 1905–1913. doi: 10.1002/cncr.22610
61. Collins, B., Mackenzie, J., Stewart, A., Bielajew, C., & Verma, S. (2008). Cognitive effects of chemotherapy in post‐menopausal breast cancer patients 1 year after treatment. Psycho-Oncology, 18(2), 134–143. doi: 10.1002/pon.1379
62. Bigotte, L., Arvidson, B., & Olsson, Y. (1982). Cytofluorescence localization of adriamycin in the nervous system. Acta Neuropathologica, 57(2–3), 121–129. doi: 10.1007/bf00685379
63. Sritharan, S., & Sivalingam, N. (2021). A comprehensive review on time-tested anticancer drug doxorubicin. Life Sciences, 278, 119527. doi: 10.1016/j.lfs.2021.119527
64. Turrens, J. F. (2003). Mitochondrial formation of reactive oxygen species. The Journal of Physiology, 552(2), 335–344. doi: 10.1113/jphysiol.2003.049478
65. Cho, K.-J., Seo, J.-M., & Kim, J.-H. (2011). Bioactive Lipoxygenase Metabolites Stimulation of NADPH Oxidases and Reactive Oxygen Species. Molecules and Cells, 32(1), 1–6. doi: 10.1007/s10059-011-1021-7
66. Bae, Y. S., Oh, H., Rhee, S. G., & Yoo, Y. D. (2011). Regulation of Reactive Oxygen Species Generation in Cell Signaling. Molecules and Cells, 32(6), 491–509. doi: 10.1007/s10059-011-0276-3
67. Berthiaume, J. M., & Wallace, K. B. (2006). Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biology and Toxicology, 23(1), 15–25. doi: 10.1007/s10565-006-0140-y
68. Zorov, D. B., Filburn, C. R., Klotz, L.-O., Zweier, J. L., & Sollott, S. J. (2000). Reactive Oxygen Species (Ros-Induced) Ros Release. The Journal of Experimental Medicine, 192(7), 1001–1014. doi: 10.1084/jem.192.7.1001
69. Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S. V. N., Mutharasan, R. K., Naik, T. J., & Ardehali, H. (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. Journal of Clinical Investigation, 124(2), 617–630. doi: 10.1172/jci72931
70. Sawyer, D. B. (2013). Anthracyclines and Heart Failure. New England Journal of Medicine, 368(12), 1154–1156. doi: 10.1056/nejmcibr1214975
71. Nozaki, N., Shishido, T., Takeishi, Y., & Kubota, I. (2004). Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout Mice. Circulation, 110(18), 2869–2874. doi: 10.1161/01.cir.0000146889.46519.27
72. Tsujimura, H., Tamura, T., Kong, H. J., Nishiyama, A., Ishii, K. J., Klinman, D. M., & Ozato, K. (2004). Toll-Like Receptor 9 Signaling Activates NF-κB through IFN Regulatory Factor-8/IFN Consensus Sequence Binding Protein in Dendritic Cells. The Journal of Immunology, 172(11), 6820–6827. doi: 10.4049/jimmunol.172.11.6820
73. L’Ecuyer, T., Sanjeev, S., Thomas, R., Novak, R., Das, L., Campbell, W., & Heide, R. V. (2006). DNA damage is an early event in doxorubicin-induced cardiac myocyte death. American Journal of Physiology-Heart and Circulatory Physiology, 291(3), H1273–H1280. doi: 10.1152/ajpheart.00738.2005
74. Shizukuda, Y., Matoba, S., Mian, O. Y., Nguyen, T., & Hwang, P. M. (2005). Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Molecular and Cellular Biochemistry, 273(1–2), 25–32. doi: 10.1007/s11010-005-5905-8
75. Chacon, E. (1991). Mitochondrial regulation of superoxide by Ca2+: An alternate mechanism for the cardiotoxicity of doxorubicin. Toxicology and Applied Pharmacology, 107(1), 117–128. doi: 10.1016/0041-008x(91)90336-d
76. Skulachev, V. P. (1997). Membrane-Linked Systems Preventing Superoxide Formation. Bioscience Reports, 17(3), 347–366. doi: 10.1023/a:1027344914565
77. Skulachev, V. P. (2000). Mitochondria in the Programmed Death Phenomena; A Principle of Biology: “It Is Better to Die than to be Wrong.” IUBMB Life, 49(5), 365–373. doi: 10.1080/152165400410209
78. Hengartner, M. O. (2000). The biochemistry of apoptosis. Nature, 407(6805), 770–776. doi: 10.1038/35037710
79. Arola, O. J., Saraste, A., Pulkki, K., Kallajoki, M., Parvinen, M., & Voipio-Pulkki, L. M. (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer research, 60(7), 1789–1792.
80. Héon, S., Bernier, M., Servant, N., Dostanic, S., Wang, C., Kirby, G. M., Alpert, L., & Chalifour, L. E. (2003). Dexrazoxane does not protect against doxorubicin-induced damage in young rats. American Journal of Physiology-Heart and Circulatory Physiology, 285(2), H499–H506. doi: 10.1152/ajpheart.00047.2003
81. Childs, A. C., Phaneuf, S. L., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer research, 62(16), 4592–4598.
82. Wang, G. W., Klein, J. B., & Kang, Y. J. (2001). Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. The Journal of pharmacology and experimental therapeutics, 298(2), 461–468.
83. Zhu, J., Zhang, J., Zhang, L., Du, R., Xiang, D., Wu, M., Zhang, R., & Han, W. (2011). Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. Biomedicine & Pharmacotherapy, 65(7), 481–485. doi: 10.1016/j.biopha.2011.06.005
84. Saleem, M. T. S., Chetty, M. C., & Kavimani, S. (2014). Antioxidants and tumor necrosis factor alpha-inhibiting activity of sesame oil against doxorubicin-induced cardiotoxicity. Therapeutic Advances in Cardiovascular Disease, 8(1), 4–11. doi: 10.1177/1753944713516532
85. Sun, Z., Yan, B., Yu, W. Y., Yao, X., Ma, X., Sheng, G., & Ma, Q. (2016). Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. Experimental and Therapeutic Medicine, 12(3), 1879–1884. doi: 10.3892/etm.2016.3518
86. Abd El-Aziz, T. A., Mohamed, R. H., Pasha, H. F., & Abdel-Aziz, H. R. (2011). Catechin protects against oxidative stress and inflammatory-mediated cardiotoxicity in adriamycin-treated rats. Clinical and Experimental Medicine, 12(4), 233–240. doi: 10.1007/s10238-011-0165-2
87. GUO, R.-M., XU, W.-M., LIN, J.-C., MO, L.-Q., HUA, X.-X., CHEN, P.-X., WU, K., ZHENG, D.-D., & FENG, J.-Q. (2013). Activation of the p38 MAPK/NF-κB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. Molecular Medicine Reports, 8(2), 603–608. doi: 10.3892/mmr.2013.1554
88. Pecoraro, M., Del Pizzo, M., Marzocco, S., Sorrentino, R., Ciccarelli, M., Iaccarino, G., Pinto, A., & Popolo, A. (2016). Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicology and Applied Pharmacology, 293, 44–52. doi: 10.1016/j.taap.2016.01.006
89. Shaker, R. A., Abboud, S. H., Assad, H. C., & Hadi, N. (2018). Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis. BMC Pharmacology and Toxicology, 19(1). doi: 10.1186/s40360-017-0184-z
90. Prasanna, P. L., Renu, K., & Valsala Gopalakrishnan, A. (2020). New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sciences, 250, 117599. doi: 10.1016/j.lfs.2020.117599
91. Slivnick, J., Vallakati, A., Addison, D., Wallner, A., & Tong, M. S. (2020). Personalized Approach to Cancer Treatment–Related Cardiomyopathy. Current Heart Failure Reports, 17(2), 43–55. doi: 10.1007/s11897-020-00453-3
92. Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005). Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies. British Journal of Haematology, 131(5), 561–578. doi: 10.1111/j.1365-2141.2005.05759.x
93. Al-Kuraishy, H., & Al-Gareeb, A. (2017). Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile. Journal of Basic and Clinical Pharmacy, 8(1), 8. doi: 10.4103/0976-0105.195080
94. Ahmed, I. A. (2018). Ameliorating the anticancer drug ”Adriamycin” acute Cardiotoxicity by Rosuvastatin and Telmisartan in rats. Iraqi Journal of Cancer and Medical Genetics, 7(2). doi: 10.29409/ijcmg.v7i2.138
95. Al-Kuraishy, H. M., & Al-Gareeb, A.I. (2015). Cardio-protective effects of cyclosporine in doxorubicin induced cardiotoxicity and assessment of Interleukin-17 as biomarker of cardiac injury: an animal model study. Advances in Biomedicine and Pharmacy, 2(3), 138–145.
96. Al-Kurashiy, H. M. K., Abdalwahab, I. N., Algareeb, A. I. A., & Alwindy, S. B. (2011). Effects of Carvedilol on the Exercise Parameters. Journal of Al-Nahrain University Science, 14(4), 121–125. doi: 10.22401/jnus.14.4.16
97. Rao, M. R., Palada, M. C., & Becker, B. N. (2004). Medicinal and aromatic plants in agroforestry systems. Agroforestry Systems, 61–62(1–3), 107–122. doi: 10.1023/b:agfo.0000028993.83007.4b
98. Sun, Z., Yan, B., Yu, W. Y., Yao, X., Ma, X., Sheng, G., & Ma, Q. (2016). Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. Experimental and Therapeutic Medicine, 12(3), 1879–1884. doi: 10.3892/etm.2016.3518
99. Kim, H. K., Park, S. K., Zhou, J.-L., Taglialatela, G., Chung, K., Coggeshall, R. E., & Chung, J. M. (2004). Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain. Pain, 111(1), 116–124. doi: 10.1016/j.pain.2004.06.008
100. Kapadia, G., A. Azuine, M., Subba Rao, G., Arai, T., Iida, A., & Tokuda, H. (2011). Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines. Anti-Cancer Agents in Medicinal Chemistry, 11(3), 280–284. doi: 10.2174/187152011795347504
101. Villarino, B. J., Dy, L. M., & Lizada, Ma. C. C. (2007). Descriptive sensory evaluation of virgin coconut oil and refined, bleached and deodorized coconut oil. LWT - Food Science and Technology, 40(2), 193–199. doi: 10.1016/j.lwt.2005.11.007
102. Salian, V., & Shetty, P. (2018). Coconut Oil and Virgin Coconut Oil: An Insight into its Oral and Overall Health Benefits. Journal of Clinical and Diagnostic Research. doi: 10.7860/jcdr/2018/31409.11051
103. Zakaria, Z. A., Somchit, M. N., Mat Jais, A. M., Teh, L. K., Salleh, M. Z., & Long, K. (2011). In vivo Antinociceptive and Anti-inflammatory Activities of Dried and Fermented Processed Virgin Coconut Oil. Medical Principles and Practice, 20(3), 231–236. doi: 10.1159/000323756
104. Kappally, S., Shirwaikar, A., & Shirwaikar, A. (2015). Coconut oil- a review of potential applications. Hygeia Journal for Drugs and Medicines, 7(2). doi: 10.15254/h.j.d.med.7.2015.149
105. Varma, S. R., Sivaprakasam, T. O., Arumugam, I., Dilip, N., Raghuraman, M., Pavan, K. B., Rafiq, M., & Paramesh, R. (2019). In vitro anti-inflammatory and skin protective properties of Virgin coconut oil. Journal of Traditional and Complementary Medicine, 9(1), 5–14. doi: 10.1016/j.jtcme.2017.06.012
106. Marina, A. M., Che man, Y. B., Nazimah, S. A. H., & Amin, I. (2009). Antioxidant capacity and phenolic acids of virgin coconut oil. International Journal of Food Sciences and Nutrition, 60(sup2), 114–123. doi: 10.1080/09637480802549127
107. Zentek, J., Buchheit-Renko, S., Ferrara, F., Vahjen, W., Van Kessel, A. G., & Pieper, R. (2011). Nutritional and physiological role of medium-chain triglycerides and medium-chain fatty acids in piglets. Animal Health Research Reviews, 12(1), 83–93. doi: 10.1017/s1466252311000089
108. Fernando, W. M. A. D. B., Martins, I. J., Goozee, K. G., Brennan, C. S., Jayasena, V., & Martins, R. N. (2015). The role of dietary coconut for the prevention and treatment of Alzheimer’s disease: potential mechanisms of action. British Journal of Nutrition, 114(1), 1–14. doi: 10.1017/s0007114515001452
109. Subermaniam, K., Saad, Q. H. M., Das, S., & Othman, F. (2014). Virgin Coconut Oil (VCO) Decreases the Level of Malondialdehyde (MDA) in the Cardiac Tissue of Experimental Sprague-Dawley Rats Fed with Heated Palm O. Journal of Medical and Bioengineering, 3(2), 102–106. doi: 10.12720/jomb.3.2.102-106
110. Lappano, R., Sebastiani, A., Cirillo, F., Rigiracciolo, D. C., Galli, G. R., Curcio, R., Malaguarnera, R., Belfiore, A., Cappello, A. R., & Maggiolini, M. (2017). The lauric acid-activated signaling prompts apoptosis in cancer cells. Cell Death Discovery, 3(1). doi: 10.1038/cddiscovery.2017.63
111. Kamaladin, N. N., Yusop, M. R., & Sulaiman, S. A. (2015). Apoptosis in lung cancer cells induced by virgin coconut oil. Regenerative Research, 4, 30-36.
112. Alghamdi, B. S. A. (2018). Possible prophylactic anti-excitotoxic and anti-oxidant effects of virgin coconut oil on aluminium chloride-induced Alzheimer’s in rat models. Journal of Integrative Neuroscience, 17(3–4), 593–607. doi: 10.3233/jin-180089
113. Rahim, N. S., Lim, S. M., Mani, V., Hazalin, N. A. M. N., Majeed, A. B. A., & Ramasamy, K. (2020). Virgin Coconut Oil-Induced Neuroprotection in Lipopolysaccharide-Challenged Rats is Mediated, in Part, Through Cholinergic, Anti-Oxidative and Anti-Inflammatory Pathways. Journal of Dietary Supplements, 18(6), 655–681. doi: 10.1080/19390211.2020.1830223
114. Rahim, N. S., Lim, S. M., Mani, V., Abdul Majeed, A. B., & Ramasamy, K. (2017). Enhanced memory in Wistar rats by virgin coconut oil is associated with increased antioxidative, cholinergic activities and reduced oxidative stress. Pharmaceutical Biology, 55(1), 825–832. doi: 10.1080/13880209.2017.1280688
115. Dulin, B., & Abraham, W. T. (2004). Pharmacology of carvedilol. The American Journal of Cardiology, 93(9), 3–6. doi: 10.1016/j.amjcard.2004.01.003
116. Cheng, J., Kamiya, K., & Kodama, I. (2001). Carvedilol: Molecular and Cellular Basis for Its Multifaceted Therapeutic Potential. Cardiovascular Drug Reviews, 19(2), 152–171. doi: 10.1111/j.1527-3466.2001.tb00061.x
117. Elitok, A., Oz, F., Cizgici, A. Y., Kilic, L., Ciftci, R., Sen, F., Bugra, Z., Mercanoglu, F., Oncul, A., & Oflaz, H. (2014). Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiology Journal, 21(5), 509–515. doi: 10.5603/cj.a2013.0150
118. Khand, A. U., Chew, P. G., Douglas, H., Jones, J., Jan, A., & Cleland, J. G. F. (2015). The Effect of Carvedilol on B-Type Natriuretic Peptide and Cardiac Function in Patients with Heart Failure and Persistent Atrial Fibrillation. Cardiology, 130(3), 153–158. doi: 10.1159/000368746
119. Mitry, M. A., & Edwards, J. G. (2016). Doxorubicin induced heart failure: Phenotype and molecular mechanisms. IJC Heart & Vasculature, 10, 17–24. doi: 10.1016/j.ijcha.2015.11.004
120. Sari, F. R., Arozal, W., Watanabe, K., Harima, M., Veeravedu, P. T., Thandavarayan, R. A., Suzuki, K., Arumugam, S., Soetikno, V., & Kodama, M. (2011). Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin-Induced Rats. Pharmaceuticals, 4(3), 551–566. doi: 10.3390/ph4030551
121. Ibrahim, S. S., Barakat, M. A., & Helmy, H. S. (2010). Modulating effect of carvedilol on doxorubicin-induced cardiomyopathy and hepatic damage. Journal of American Science, 6, 20-32.
122. Poole-Wilson, P. A., Swedberg, K., Cleland, J. G., Di Lenarda, A., Hanrath, P., Komajda, M., Lubsen, J., Lutiger, B., Metra, M., Remme, W. J., Torp-Pedersen, C., Scherhag, A., & Skene, A. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet, 362(9377), 7–13. doi: 10.1016/s0140-6736(03)13800-7
123. Baker, J. G. (2005). The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. British Journal of Pharmacology, 144(3), 317–322. doi: 10.1038/sj.bjp.0706048
124. Molenaar, P., Christ, T., Ravens, U., & Kaumann, A. (2006). Carvedilol blocks β2- more than β1-adrenoceptors in human heart. Cardiovascular Research, 69(1), 128–139. doi: 10.1016/j.cardiores.2005.08.024
125. Zhang, D. X., Ma, D. Y., Yao, Z. Q., Fu, C. Y., Shi, Y. X., Wang, Q. L., & Tang, Q. Q. (2016). ERK1/2/p53 and NF-κB dependent-PUMA activation involves in doxorubicin-induced cardiomyocyte apoptosis. European review for medical and pharmacological sciences, 20(11), 2435–2442.
126. Abshagen U. (1987). A new molecule with vasodilating and beta-adrenoceptor blocking properties. Journal of cardiovascular pharmacology, 10 Suppl 11, S23–S32.
127. Kalinowski, L., Dobrucki, L. W., Szczepanska-Konkel, M., Jankowski, M., Martyniec, L., Angielski, S., & Malinski, T. (2003). Third-Generation β-Blockers Stimulate Nitric Oxide Release From Endothelial Cells Through ATP Efflux. Circulation, 107(21), 2747–2752. doi: 10.1161/01.cir.0000066912.58385.de
128. Nichols, A., Gellai, M., & Ruffolo, R. (1991). Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundamental & Clinical Pharmacology, 5(1), 25–38. doi: 10.1111/j.1472-8206.1991.tb00698.x
129. Prichard, B. N. C., & Tomlinson, B. (1988). Progress in Antihypertensive Therapy with a Multiple-Action Drug. Drugs, 36(Supplement 6), 20–25. doi: 10.2165/00003495-198800366-00005
130. Huang, K. M., Liang, S., Yeung, S., Oiyemhonlan, E., Cleveland, K. H., Parsa, C., Orlando, R., Meyskens, F. L., Andresen, B. T., & Huang, Y. (2017). Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis. Cancer Prevention Research, 10(10), 598–606. doi: 10.1158/1940-6207.capr-17-0132
131. Chang, A., Yeung, S., Thakkar, A., Huang, K. M., Liu, M. M., Kanassatega, R.-S., Parsa, C., Orlando, R., Jackson, E. K., Andresen, B. T., & Huang, Y. (2015). Prevention of Skin Carcinogenesis by the β-Blocker Carvedilol. Cancer Prevention Research, 8(1), 27–36. doi: 10.1158/1940-6207.capr-14-0193
132. Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., & Cipolla, C. M. (2016). Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA: A Cancer Journal for Clinicians, 66(4), 309–325. doi: 10.3322/caac.21341
133. Colasanti, M., & Suzuki, H. (2000). The dual personality of NO. Trends in Pharmacological Sciences, 21(7), 249–252. doi: 10.1016/s0165-6147(00)01499-1
134. Boje, K., M. K. (2004). Nitric oxide neurotoxicity in neurodegenerative diseases. Frontiers in Bioscience, 9(1–3), 763. doi: 10.2741/1268
135. Akyol, O., Zoroglu, S. S., Armutcu, F., Sahin, S., & Gurel, A. (2004). Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In vivo (Athens, Greece), 18(3), 377–390.
136. Puzzo, D., Vitolo, O., Trinchese, F., Jacob, J. P., Palmeri, A., & Arancio, O. (2005). Amyloid-β Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity. The Journal of Neuroscience, 25(29), 6887–6897. doi: 10.1523/jneurosci.5291-04.2005
137. Abd El‐Gawad, H. M., & El‐Sawalhi, M. M. (2004). Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: Role of aminoguanidine. Journal of Biochemical and Molecular Toxicology, 18(2), 69–77. doi: 10.1002/jbt.20013
138. Afonso, R., Patarrao, R., Macedo, M., & Carmo, M. (2006). Carvedilol Action Is Dependent on Endogenous Production of Nitric Oxide. American Journal of Hypertension, 19(4), 419–425. doi: 10.1016/j.amjhyper.2005.11.011
139. Macedo, M. P., & Lautt, W. W. (1996). Shear-induced modulation by nitric oxide of sympathetic nerves in the superior mesenteric artery. Canadian journal of physiology and pharmacology, 74(6), 692–700.
140. Zucker, I. H., Schultz, H. D., Li, Y.-F., Wang, Y., Wang, W., & Patel, K. P. (2004). The origin of sympathetic outflow in heart failure: the roles of angiotensin II and nitric oxide. Progress in Biophysics and Molecular Biology, 84(2–3), 217–232. doi: 10.1016/j.pbiomolbio.2003.11.010
141. Hu, H., Chiamvimonvat, N., Yamagishi, T., & Marban, E. (1997). Direct inhibition of expressed cardiac L-type Ca2+ channels by S-nitrosothiol nitric oxide donors. Circulation research, 81(5), 742–752. doi: 10.1161/01.res.81.5.742
142. Famurewa, A. C., Maduagwuna, E. K., Folawiyo, A. M., Besong, E. E., Eteudo, A. N., Famurewa, O. A., & Ejezie, F. E. (2020). Antioxidant, anti-inflammatory, and antiapoptotic effects of virgin coconut oil against antibiotic drug gentamicin-induced nephrotoxicity via the suppression of oxidative stress and modulation of iNOS/NF-ĸB/caspase-3 signaling pathway in Wistar rats. Journal of food biochemistry, 44(1), e13100. doi: 10.1111/jfbc.13100
143. Kurosaki, K., Ikeda, U., Maeda, Y., & Shimada, K. (2000). Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. Journal of molecular and cellular cardiology, 32(2), 333–339. doi: 10.1006/jmcc.1999.1079
144. Ishiyama, S., Hiroe, M., Nishikawa, T., Abe, S., Shimojo, T., Ito, H., Ozasa, S., Yamakawa, K., Matsuzaki, M., Mohammed, M. U., Nakazawa, H., Kasajima, T., & Marumo, F. (1997). Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation, 95(2), 489–496. doi: 10.1161/01.cir.95.2.489
145. Pacher, P., Schulz, R., Liaudet, L., & Szabó, C. (2005). Nitrosative stress and pharmacological modulation of heart failure. Trends in pharmacological sciences, 26(6), 302–310. doi: 10.1016/j.tips.2005.04.003
146. MacEwan D. J. (2002). TNF ligands and receptors--a matter of life and death. British journal of pharmacology, 135(4), 855–875. doi: 10.1038/sj.bjp.0704549
147. Nishioku, T., Matsumoto, J., Dohgu, S., Sumi, N., Miyao, K., Takata, F., Shuto, H., Yamauchi, A., & Kataoka, Y. (2010). Tumor necrosis factor-alpha mediates the blood-brain barrier dysfunction induced by activated microglia in mouse brain microvascular endothelial cells. Journal of pharmacological sciences, 112(2), 251–254. doi: 10.1254/jphs.09292sc
148. Butler, M. P., O'Connor, J. J., & Moynagh, P. N. (2004). Dissection of tumor-necrosis factor-alpha inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early-but not late-phase LTP. Neuroscience, 124(2), 319–326. doi: 10.1016/j.neuroscience.2003.11.040
149. Riad, A., Bien, S., Gratz, M., Escher, F., Westermann, D., Heimesaat, M. M., Bereswill, S., Krieg, T., Felix, S. B., Schultheiss, H. P., Kroemer, H. K., & Tschöpe, C. (2008). Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. European journal of heart failure, 10(3), 233–243. doi: 10.1016/j.ejheart.2008.01.004
150. Riad, A., Bien, S., Westermann, D., Becher, P. M., Loya, K., Landmesser, U., Kroemer, H. K., Schultheiss, H. P., & Tschöpe, C. (2009). Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer research, 69(2), 695–699. doi: 10.1158/0008-5472.CAN-08-3076
151. Sauter, K. A., Wood, L. J., Wong, J., Iordanov, M., & Magun, B. E. (2011). Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer biology & therapy, 11(12), 1008–1016. doi: 10.4161/cbt.11.12.15540
152. Gilliam, L. A., Moylan, J. S., Ferreira, L. F., & Reid, M. B. (2011). TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness. American journal of physiology. Lung cellular and molecular physiology, 300(2), L225–L231. doi: 10.1152/ajplung.00264.2010
153. Benzer, F., Kandemir, F. M., Ozkaraca, M., Kucukler, S., & Caglayan, C. (2018). Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats. Journal of biochemical and molecular toxicology, 32(2). doi: 10.1002/jbt.22030
154. Keeney, J. (2013). Doxorubicin-induced TNF- α-mediated brain oxidative stress, neurochemical alterations, and cognitive decline: insights into mechanisms of chemotherapy induced cognitive impairment and its prevention (Doctoral thesis). Retrieved from https://uknowledge.uky.edu/chemistry_etds/27/
155. Hyka, N., Dayer, J. M., Modoux, C., Kohno, T., Edwards, C. K., 3rd, Roux-Lombard, P., & Burger, D. (2001). Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood, 97(8), 2381–2389. doi: 10.1182/blood.v97.8.2381
156. Spallarossa, P., Garibaldi, S., Altieri, P., Fabbi, P., Manca, V., Nasti, S., Rossettin, P., Ghigliotti, G., Ballestrero, A., Patrone, F., Barsotti, A., & Brunelli, C. (2004). Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. Journal of molecular and cellular cardiology, 37(4), 837–846. doi: 10.1016/j.yjmcc.2004.05.024
157. Vysakh, A., Ratheesh, M., Rajmohanan, T. P., Pramod, C., Premlal, S., Girish kumar, B., & Sibi, P. I. (2014). Polyphenolics isolated from virgin coconut oil inhibits adjuvant induced arthritis in rats through antioxidant and anti-inflammatory action. International immunopharmacology, 20(1), 124–130. doi: 10.1016/j.intimp.2014.02.026
158. Cinquegrana, G., D'Aniello, L., Landi, M., Spinelli, L., Grande, G., De Prisco, F., & Petretta, M. (2005). Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. Journal of cardiac failure, 11(3), 213–219. doi: 10.1016/j.cardfail.2004.07.006
159. Borai, I. H., Ezz, M. K., Rizk, M. Z., Aly, H. F., El-Sherbiny, M., Matloub, A. A., & Fouad, G. I. (2017). Therapeutic impact of grape leaves polyphenols on certain biochemical and neurological markers in AlCl3-induced Alzheimer's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 93, 837–851. doi: 10.1016/j.biopha.2017.07.038
160. Kuzu, M., Kandemir, F. M., Yildirim, S., Kucukler, S., Caglayan, C., & Turk, E. (2018). Morin attenuates doxorubicin-induced heart and brain damage by reducing oxidative stress, inflammation and apoptosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 106, 443–453. doi: 10.1016/j.biopha.2018.06.161
161. Pal, S., Ahir, M., & Sil, P. C. (2012). Doxorubicin-induced neurotoxicity is attenuated by a 43-kD protein from the leaves of Cajanus indicus L. via NF-κB and mitochondria dependent pathways. Free radical research, 46(6), 785–798. doi: 10.3109/10715762.2012.678841
162. Khadrawy, Y. A., Hosny, E. N., & Mohammed, H. S. (2021). Protective effect of nanocurcumin against neurotoxicity induced by doxorubicin in rat's brain. Neurotoxicology, 85, 1–9. doi: 10.1016/j.neuro.2021.04.003
163. Gonzalez, Y., Pokrzywinski, K. L., Rosen, E. T., Mog, S., Aryal, B., Chehab, L. M., Vijay, V., Moland, C. L., Desai, V. G., Dickey, J. S., & Rao, V. A. (2015). Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to Doxorubicin in tumor-bearing spontaneously hypertensive rats. Cancer chemotherapy and pharmacology, 76(3), 447–459. doi: 10.1007/s00280-015-2786-8
164. Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995). Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. The New England journal of medicine, 332(26), 1738–1743. doi: 10.1056/NEJM199506293322602
165. Zhang, J., Knapton, A., Lipshultz, S. E., Cochran, T. R., Hiraragi, H., & Herman, E. H. (2014). Sex-related differences in mast cell activity and doxorubicin toxicity: a study in spontaneously hypertensive rats. Toxicologic pathology, 42(2), 361–375. doi: 10.1177/0192623313482778
166. Moulin, M., Solgadi, A., Veksler, V., Garnier, A., Ventura-Clapier, R., & Chaminade, P. (2015). Sex-specific cardiac cardiolipin remodelling after doxorubicin treatment. Biology of sex differences, 6, 20. doi: 10.1186/s13293-015-0039-5
167. van Hoesel, Q. G., Steerenberg, P. A., Dormans, J. A., de Jong, W. H., de Wildt, D. J., & Vos, J. G. (1986). Time-course study on doxorubicin-induced nephropathy and cardiomyopathy in male and female LOU/M/Wsl rats: lack of evidence for a causal relationship. Journal of the National Cancer Institute, 76(2), 299–307.
168. Julicher, R. H., Sterrenberg, L., Haenen, G. R., Bast, A., & Noordhoek, J. (1988). The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat. Archives of toxicology, 61(4), 275–281. doi: 10.1007/BF00364850
169. Julicher, R. H., Sterrenberg, L., Haenen, G. R., Bast, A., & Noordhoek, J. (1984). Sex differences in the cellular defence system against free radicals from oxygen or drug metabolites in rat. Archives of toxicology, 56(2), 83–86. doi: 10.1007/BF00349076
Article Metrics
Metrics powered by PLOS ALM
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Ezeh Anthonia Chiamaka, Egbe Justine Uchechukwu, Dike Sandra Chioma, Ruth Asonye, Onuh Kenneth Chijioke, Divine Chidinma Chiemela
This work is licensed under a Creative Commons Attribution 4.0 International License.
Email the author